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INTRODUTION
On March 12, 2019, an Advisory Board on im-
pact of uterine bleedings on the quality of life of 
a woman was held in Kyiv, with participation of 
leading Ukrainian and European experts, which 
have an experience in researching of this prob-
lem. During the meeting special attention was 
paid on a role and place of prolonged and/or 
heavy menses in the formation of premenstrual 
symptoms and, respectively, the development of 
premenstrual syndrome (PMS) and premenstrual 
dysphoric disorder. 
Taking into consideration modern regulato-
ry documents, which define abnormal uterine 
bleedings (AUB) diagnostics and treatment in 
Ukraine, it is stated that the use of the recom-
mendations which is listed in the Unified clinical 
protocol “Abnormal uterine bleedings“ approved 
by the MoH of Ukraine №353 of April 13, 2016 
[42], currently allows to adequately detect and 
treat this pathology and meets the modern in-
ternational standards, first of all, the Guideline 
of International Federation of Gynecology and 
Obstetrics (FIGO) of 2011. However, this docu-
ment does not set out an assessment of month-
ly bleedings impact on women’s quality of life 
and today quite often both women and physi-
cians underestimate the duration and menstrual 
bleeding loss and do not take into consideration 
a number of symptoms caused by heavy and 
prolonged menstruation. This causes a lack of 
appropriate management of this pathology. 
The complexity of the problem of AUB in 
non-pregnant women is largely relates to the 
fact that they can be a manifestation of different 
by their nature disorders. In 2011, the interna-
tional expert group under the auspices of FIGO 
has developed uterine bleedings classification 
system PALM-COEIN, which has been adopted in 
Ukraine, in the most other European countries, 
USA and Canada. The FIGO classification sys-
tem includes 9 categories of AUB, 4 of which are 
caused by uterine pathology (PALM: polyp, ad-
enomyosis, leiomyoma and malignancy/hyper-
plasia), and 5 are not related to organic changes 
(COEIN: coagulopathy, ovulatory dysfunction, 
endometrial dysfunction, iatrogenic causes, as 
well as a category that includes yet unclassified 
disorders) [40].
In 2018, changes were made to the PALM-COE-
IN classification, in particular: the diagnostic cri-
teria for adenomyosis were specified; AUB relat-
ed to the use of anticoagulants and medicines, 
that suppress ovulation were categorized as AUB 
related to iatrogenic processes; a new potential 
cause of AUB, so-called “niche“ of the uterus or 
an isthmocele after a caesarean section of the 
lower segment of the uterus, is attributed to the 
category “not otherwise unclassified“ [40]. 
The updated in 2018 international recommen-
dations (guideline of the UK National Institute for 
Health and Care Excellence (NICE) and FIGO) also 
offered a modern characteristics of parameters 
of normal menstrual cycle (Table) and the man-
agement of its possible disorders, which must be 
given special attention in clinical practice.
Such parameters of menstrual cycle as regu-
larity, frequency and duration are relatively easy 
to establish based on menstrual calendar data, 
whereas menstrual blood loss is a rather subjec-
tive indicator. 
Usually the threshold for diagnostics of heavy 
menstrual bleeding is considered to be men-
strual blood loss >80 ml, but it should be noted 
that iron deficiency is already observed in case 
of monthly blood loss of more than 60 ml. There-
fore, according to the opinion of international ex-
perts (NICE and FIGO recommendations, 2018), 
the choice of patient management tactics is de-
termined not by blood loss measurement, but 
the patient's sense of well-being (distress, de-
crease of work ability, sexual activity and quality 
of life in general) [40, 41]. In women with acute or 
chronic AUB, a laboratory assessment of serum 
ferritin level should be conducted to detect iron 
deficiency and hemoglobin and/or hematocrit (it 
is advisable to conduct a general blood test) to 
diagnose anemia [40]. 
SYSTEMIC BIOLOGICAL EFFECTS 
OF MENSTRUATION 
Historically, in all cultures, monthly bleedings 
in women were considered as the norm and 
even as a “purification” process. Why in recent 
decades so much attention has been paid to 
studying the problem of menstrual bleeding? 
That is why for millennia, and until the begin-
ning of the 20th century, women experienced 
from 140 to 160 menstrual periods throughout 
their lives. Today a woman has an average of 
450–480 menstruations, which means that their 
number has tripled [1, 2] in only 100 years, that 
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is a “blinking time”, in comparison to the 
evolution time of the Homo sapiens, 
estimated around 200 000 years. This 
huge change is related to an earlier age 
of menarche, fewer pregnancies, a de-
crease in the duration of breastfeeding 
and later menopause. 
The physiology of the menstrual cy-
cle is regulated by the fluctuations of 
5 key hormones: luteinizing hormone 
(LH) and follicle stimulating hormone 
(FSH), which are produced by cells of the 
anterior pituitary gland; estradiol, pro-
gesterone and testosterone, which are 
produced by the ovaries [1]. The molec-
ular mechanisms by which estradiol and 
progesterone control the menstrual cy-
cle include the interaction between the 
endocrine and immune systems [1, 2–8]. 
In the premenstrual phase of the cycle, 
the reduction and fall of estradiol and 
progesterone levels triggers a cascade 
of events that includes the release of in-
flammatory molecules by mast cells and 
other immune cells. 
 This causes a local and systemic in-
crease of key inflammatory mediators’ 
concentration (chemokines, inter-
leikin-8, matrix metalloproteinase-1, cy-
clooxygenase-2, an enzyme responsible 
for the synthesis of prostaglandins, as 
well as for inhibition of prostaglandin 
dehydrogenase expression). This, in turn, 
leads to an increase in the concentration 
of prostaglandins PGE2 and PGF2a [1, 8, 9]. 
In addition, a corresponding perimen-
strual migration of leukocytes and mac-
rophages occurs with a local increase 
of mast cells number [1, 2–8]. These 
cells produce and release cytokines that 
stimulate further leukocyte migration in 
endometrium. Together with the endo-
metrial stromal cells they release matrix 
metalloproteinase, which results in de-
struction of the extracellular matrix, en-
dometrial shedding and menstruation 
begin.
Mast cells play a key role in develop-
ment of inflammation, they are present 
in the endometrium and myometrium, 
and are mainly localized in the basal 
layer of the endometrium itself [1, 3–7]. 
These cells are activated in response to 
a wide range of stimuli, including neu-
rogenic factors, estrogen level fluctua-
tions, and presence of menstrual blood 
in tissue [10]. Mast cells mediators in 
myometrium are histamine, serotonin, 
heparin, bradykinin, prostaglandins, tu-
mor necrosis factor α and interleukins 
(IL-4, IL-6) [3]. 
Taking into consideration the afore-
mentioned data, today a new view is 
forming on the pathophysiological pro-
cesses, which lead to menstrual symp-
toms onset. In particular, the cyclic 
premenstrual fall of estradiol and pro-
gesterone levels triggers degranulation 
of the mast cells and other immune cells 
in different organs, where local inflam-
mation occurs in response to genetic 
and/or acquired vulnerabilities. This sce-
nario may happen: 
 in the bowel‘s wall – menstrual 
worsening of bowel symptoms such 
as in the woman suffers from irritable 
bowel syndrome (IBS); 
 in the bladder wall – menstrual flares 
of bladder pain if she is vulnerable to 
recurrent cystitis and/or if she complains 
of symptoms of bladder pain syndrome;
 in the vestibulum of the vagina – 
vestibulodynia or dyspareunia in women 
affected by vulvar vestibulitis or coital pain;
 in the myometrium – adenomyosis 
development, and also progression of en-
dometriosis in other organs (peritoneum, 
ovaries, bladder wall, bowel wall, upper 
third of the vagina, recto-vaginal septum 
and/or utero-sacral ligaments) if woman 
suffers from endometriosis; 
 in the meningeal dura mater and 
brain – headache worsening during 
menstruation if woman suffers from 
menstrual headache; 
 in the bronchi and lungs – progression 
of asthma if  woman suffers from it (27% of 
asthmatic women suffers from menstrual 
attacks – up to 13 acute respiratory crisis 
per year) [38]. 
The local cyclic worsening of the in-
flammatory process causes abdominal 
and pelvic symptoms (with changes in 
the state of gut microbiota, inflamma-
tion of gut walls and pain, pelvic floor 
changes, and activation of gut-brain 
axis). At the same time, the cyclic fall of 
sex hormones levels causes brain related 
symptoms (dysregulation of serotoner-
gic and dopaminergic receptors) with 
neuroinflammation and activation of the 
brain-gut axis (neurogenic bowel inflam-
mation and pain, intestinal symptoms). 
However it should be noted, that men-
strual inflammation is a physiological 
process that is necessary for the month-
ly endometrial restoration in non-preg-
nant women. Menstrual inflammation 
is physiological and menstrual symp-
toms are usually mild/minor or absent 
when three criteria are fulfilled: 
1. “resolving” (normal cytoarchitec-
ture of the tissue is reconstructed, en-
dometrium first); 
Table. System of normal menstrual cycle parameters identification (FIGO, 2018) [40]
Parameter Normal Abnormal
Frequency (interval between menstruations, days)
amenorrhea
infrequent (>38 days)
normal (≥24 – ≤38 days)
frequent (<24 days)
Duration of menstruation (days)
normal (≤8 days)
 prolonged (>8 days)
Regularity
regular (cycle variation ≤7–9 days):
18–25 years of age ≤9 days; 
26–41 years of age ≤7 days;
42–45 years of age ≤9 days
irregular (cycle variation ≥8–10 days)











Unscheduled bleeding on hormonal contraceptives 
(progestines, combined hormonal contraceptives, 
contraceptive vaginal ring, contraceptive patch) 
not applicable ( woman does not use  gonadal steroid medication)
none (woman uses gonadal steroid medication) 
present
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2. limited in time;
3. adequate and sufficient by intensity to finalize the re-
construction to the histological and functional characteris-
tics of the different tissues involved. 
At the same time, if local and systemic inflammation associat-
ed with menstruation is excessive by intensity and duration, it 
can cause both different pathological symptoms with increas-
ing severity, which associated with formation of such patholog-
ical conditions as PMS and premenstrual dysphoric disorder. 
MENSTRUAL SYMPTOMS
Vaginal bleeding is a primary genital sign of menstruation 
start. Menstruation may be accompanied by such symptoms 
as abdominal bloating and cramping, fatigue, food cravings, 
headache, mood swings, irritability and mastodynia [1]. Usu-
ally they are so frequent that they are considered as a part of 
“normal“ menstruation, and respectively considered as ones, 
that not required a high quality management. 
Heavy menstrual bleedings are associated with dysmenor-
rhea increase, iron deficiency anemia and concomitant condi-
tions (weakness, fatigue, depression, concentration and memo-
ry difficulties, poor work productivity and loss of sexual drive). As 
mentioned above other menstrual symptoms may include peri-
menstrual worsening of asthma, allergy, joint pain and myalgia. 
Dysmenorrhea and heavy menstrual bleedings
Primary dysmenorrhea is the most common the menstrual 
symptoms which occurs in about 90% of adolescents and more 
than 50% of menstruating women [11]. This pain is caused by 
uterine contractions associated with endometrial ischemia 
and with inflammatory molecules level increase (prostaglan-
dins, vasopressin, leukotrienes, and numerous mediators of 
mast cells) [1, 5, 6, 11]. According to the systematic review, in 
case of heavy menstrual bleeding, the likelihood of dysmen-
orrhea occurrence increases by more than 4 times (OR (odds 
ratio) = 4.73 (95% CI (confidence interval) 2.95–7.58)), and in 
case of prolonged bleedings – in more than 2 times (OR = 2.38 
(95% CI 1.69–3.37)) [12]. This in turn may increase the risk of 
endometriosis, which is the main cause of secondary dysmen-
orrhea and chronic pelvic pain [1, 13]. 
Chronic pelvic pain
Fluctuations of ovarian hormones during the menstrual 
cycle are associated with pain increase, which may be associ-
ated with concomitant diseases (painful bladder syndrome/
interstitial cystitis, vulvar vestibulitis/provoked vestibulodyn-
ia/vulvodynia, IBS) [10, 14]. Pelvic and systemic inflammation 
is a prerequisite of chronic pelvic pain, concomitant diseases, 
neuroinflammation and depression [1, 10, 14]. Premenstrual 
reduction of estrogen level causes and potentiates mast cells 
degranulation in organs with already existing inflammation, 
and thus leads to a significant pelvic pain increase during the 
natural menstrual cycle and during the 7-day hormone free 
interval (HFI) in women using combined oral contraceptives 
(COCs) [15].
Menstrual symptoms can also be associated with neuroin-
flammation (menstrual migraine, mood changes, sleep distur-
bances, irritability).
Menstrual migraine
In women suffering from menstrual migraines a decrease in 
circulating estrogen levels occurring 2–3 days before menstru-
ation is considered to be partially responsible for increase in 
migraine risk. Likely migraine occurrence is mediated by the 
degranulation of mast cells in dura mater and in the brain in 
synergy with up regulation of microglial cells with local release 
of inflammatory molecules [16–17].
Mood disorders
Inflammatory reactions also play an important role in the 
pathophysiology of mood disorders; in patients with depres-
sion, a higher level of proinflammatory cytokines, acute phase 
proteins, chemokines and cellular adhesion molecules is ob-
served [10, 14]. Mood disorders can also be influenced by re-
ducing fluctuations in estradiol levels and duration of HFI to 
2–4 days in women using COCs [1].
Gastrointestinal symptoms 
The gastrointestinal tract is the largest immune organ of the 
organism; it is intensively innervated and contains mast cells, 
receptors for immune mediators and neuropeptides. In wom-
en with IBS [19], the severity of symptoms varies during the 
menstrual cycle and tends to increase in the perimenstrual pe-
riod. Compared to healthy women, women with IBS have more 
severe gastrointestinal symptoms associated with menstrual 
cycles (cramps, abdominal bloating, diarrhea and/or constipa-
tion). 
Bronchial asthma 
It is shown that the intensity of bronchial asthma manifesta-
tion varies during the menstrual cycle. Bronchial hyperactivity 
is more likely in the perimenstrual period than in other days 
of the cycle [20]. One third of the cases of acute respiratory 
distress in symptomatic women prevail during menstruation, 
leading to so-called perimenstrual asthma, which is related to 
increase in emergency department visits. Taking into account 
that reduction of estradiol and progesterone levels during 
menstrual cycle causes asthmatic crises in vulnerable women, 
new preventive strategies that are pathophysiologically orient-
ed such as hormones levels stabilizing and reducing of COCs 
HFI interval can be proposed [1]. However, prospective, con-
trolled trials are needed to prove it.
Menstrual bleeding is a genital sign of systemic endocrine 
and inflammatory events. Severe menstrual symptoms are 
clinically correlated with local and systemic inflammation, 
which is not resolving (menstruation is excessive in duration 
and intensity, i.e. is not physiological). Therefore, reducing 
menstrual inflammation is important to reduce the frequen-
cy and intensity of menstrual symptoms and improve the 
quality of life of women of reproductive age.
Women need appropriate stable levels of estrogen and 
progesterone to optimize their physical and mental health.
BIOLOGICAL EFFECTS OF COCs USE
Today COCs are the most widely used contraceptives with 
more than 100 million users worldwide [21]. COCs not only ef-
fectively prevent pregnancy, but also have additional non-con-
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traceptive benefits. Since the development of the first contra-
ceptive pill (in the sixties of the previous century), COCs have 
undergone significant changes, which were most focused on 
reducing the dose of the estrogen component and the devel-
opment of innovative progestogens with different pleiotropic 
effects. Historically traditional regimen of COCs (21+7) imitated 
the menstrual cycle for psychological reasons: also in the fifties 
women were “afraid” of amenorrhea as it was the first sign of a 
new (often unwanted) pregnancy, particularly when the fami-
ly already had many children. The monthly “reassurance” of the 
cyclic bleeding was therefore considered essential for the pill to 
be accepted. However, the presence of a monthly withdrawal 
bleeding is not biologically necessary, from the strictly phys-
iological point of view. Before express pregnancy tests were 
available, withdrawal bleeding served indeed as a signal for a 
woman taking COCs that she was not pregnant. However, there 
are currently not enough arguments regarding the need for 
menstruation during COCs use, and taking into consideration 
the abovementioned biological effects of menstruation, women 
using COCs need stable levels of estrogen and progesterone, the 
strongest indication being for women with different menstrual 
symptoms. [1]. 
According to the updated guidelines on COC use of the Fac-
ulty of Sexual and Reproductive Health of the UK Royal College 
of Obstetricians and Gynecologists (2019) [22], the presence of 
monthly bleeding during COCs use is not beneficial for women 
health, since a 7-day HFI may be associated with such symptoms 
as headache and mood changes, dysmenorrhea and/or pelvic 
pain, although on reduced intensity in comparison to the inten-
sity of symptoms during the natural cycle. 
The persistence of symptoms during the 7 day HFI between 
one pill box and the following is well reported in women’s pain 
diary, focused on menstrual cycle.
 Inhibition of ovarian activity during HFI decreases and fol-
licle growth may occur. Mistakes in pills administration in the 
period which follows the HFI may increase the risk of ovulation 
and pregnancy that peaks if the pill is forgotten at the begin-
ning of a new box of pills.
Taking of the first 7 tablets of a new box of COCs is the most 
important biological step to inhibit ovulation, while taking of 
following 8–21 maintains anovulation. At 3–4 day of a 7-day 
HFI, the FSH level increases, and stimulates the growth of the 
follicles in the ovary with endogenous estradiol synthesis [23], 
which leads to an increase in the incidence of estrogen-relat-
ed symptoms, including nausea, mastodynia, fluid retention, 
mood changes, and headache pain. After start of COCs use 
from the next packaging, the FSH production is suppressed 
and the subsequent growth of the follicle stops, which result-
ing in follicular atresia and decrease in the concentration of 
estradiol. Similar to women who do not use hormonal con-
traceptives menstrual symptoms prevail during a 7-day HFI in 
women who use it [15]. In a study involving 262 women, pelvic 
pain, headache, mastalgia, abdominal bloating, and the need 
for analgesics use appeared much more frequently during the 
7-day HFI compared to the 21 days of active pills taking [15]. 
In case, if after a 7-day HFI the woman will forget to start tak-
ing the pills from the next packaging on time, ovulation may 
occur [24]. In a randomized cohort study involving 3030 wom-
en, it was shown that 23% of women who had been taking 
COC in 21+7 regimen missed at least 1 tablet in the previous 
cycle (n = 737). 42% of these women made a mistake in drug 
administration during the first week after the 7-day HFI [25]. A 
study on 1438 women indicates that anxious women are the 
most vulnerable to forget fullness causing an inadequate in-
take of a daily contraceptive pill [39].
According to the updated guidelines on COC use of the Fac-
ulty of Sexual and Reproductive Health of the UK Royal College 
of Obstetricians and Gynecologists (2019) [22], women can 
take COCs continuously or can shorten HFI to avoid menstrual 
bleeding and associated symptoms. However, despite the fact 
that continuous use of COCs can reduce the frequency of with-
drawal bleeding and hormone-withdrawal associated symp-
toms women may complain about irregular bleedings, which 
in turn reduces women's adherence to this regimen. It should 
be noted, the use of COC in continuous regimen is out of la-
beling. At the same time, the shortening of HFI to 4 or 2 days 
may reduce the risk of unintended pregnancy, also in case of 
mistakes in pills use [1, 25]. 
British clinical guidelines [22] also indicate, that most wom-
en may be prescribed COCs for 1 year during their first visit to 
a doctor, when a rigorous clinical history indicates adequate 
health, no contraindications and that a yearly follow-up is suf-
ficient. This may prevent the premature COC withdrawal and 
reduce the risk of unintended pregnancy. 
THE RATIONAL OF COCs HORMONE-FREE 
INTERVAL SHORTENING
The use of COCs with shortened HFI (24+4, 26+2 regimen) 
may have several benefits:
1. More effective suppression of ovulation [1, 24, 26, 27]. 
Studies have shown that during COCs use with 21+7 regimen 
follicular growth may occur during a 7-day HFI; so, the prob-
ability of an ovulation may increases when woman forgot to 
take pills from the next packaging in time [25]. 
2. Good control of the cycle (less endometrial stimulation by 
endogenous estrogen, no increase in the number of irregular 
bleedings, when using a lower dose of estrogen) [26, 28]. 
3. Reduction of genital and systemic inflammation, which is 
associated with menstruation and symptoms, associated with 
fall of estrogen and progestin that may negatively affect the 
quality of life of a woman [1]. 
4. Menstrual flow reduction, including women with heavy 
menstrual bleedings [29, 30]. 
5. Better compliance (packaging of the most COCs with 
shortened HFI contain 28 tablets (compared to COCs with 
21+7 regimen), which may help to minimize mistakes in COCs 
use from the next packaging). 
Data supporting the necessity of COCs HFI shortening 
In a study involving women, who used a combination of 20 
μg ethynilestradiol (EE) and 3 mg drospirenone (DRSP), it was 
shown that a shortening of HFI to 3–4 days provides a more 
stable suppression of LH and FSH synthesis, and prevents the 
growth of follicles during HFI [27]. 
Shortening of HFI reduces the risk of accidental ovulation 
in case of pill miss in clinical practice and increases the con-
ОХОРОНА ЗДОРОВ’Я
WWW.REPRODUCT-ENDO.COM.UA / WWW.REPRODUCT-ENDO.COM   №3(47)/червень 2019
ISSN 2309-4117 17
traceptive efficacy compare to the traditional 21+7 regimen. 
According to results of the study involving more than 50,000 
patients, in a group of women who use a combination of es-
tradiol valerate (E2V)/dienogest (DNG) with 26+2 regimen, 
the contraceptive feature rate was lower (0.9%) compared to 
combination of EE/levonorgestrel (LNG) (2,8%) and other COCs 
(2.1%) [31]. 
During COC use with 24+4 regimen, there is more pro-
nounced suppression of the follicle growth compared with 
COCs with 21+7 regimen, since in 22% of women significant 
growth of follicles (up to 13 mm) was observed during HFI [24, 
27]. It can be suggested that 24+4 regimen will be an optimal 
choice for women with a tendency to develop functional ovar-
ian cysts, since more pronounced inhibition of ovulation leads 
to a lower probability of these formations occurrence. 
For women who suffer from symptoms associated with an in-
crease in the production of endogenous sex hormones during 
the HFI, reducing the number of days without the use of hor-
mones can minimize estrogen-dependent effects (including 
premenstrual dysphoric disorder  [1, 32, 33]. During the use of 
combination of 20 μg EE/DRSP with 24+4 regimen the frequen-
cy of physical and behavioral symptoms, including those asso-
ciated with fluid retention (breast tenderness and body weight 
gain), was reduced. According to the clinical study data during 
the use of COC with 26+2 regimen (E2V/DNG) the level of estra-
diol remains stable throughout the cycle, which contributes to 
a reduction of the intensity and frequency of hormone-with-
drawal associated symptoms (headache and pelvic pain), as 
well as the reduction of the need in analgesics use during 22–
28 days of the cycle [34].
Moreover, the use of the combination of E2V/DNG with 26+2 
regimen can reduce the menstrual bleedings in women with 
heavy menstrual bleedings (by 88% after 6 months of use) [26], 
improve the iron metabolism parameters (hemoglobin, hema-
tocrit, ferritin) and increase the subjective sense of energy, 
and well-being [30]. In healthy women who use combination 
of E2V/DNG with 26+2 regimen the duration and intensity of 
withdrawal bleedings was lower compared with the use of a 
combination of 30 μg EE/LNG with 21+7 regimen [36].
CONCLUSIONS
1.  Estrogen and progesterone levels fall in the premenstrual 
phase of the cycle are associated with a number of genital (for 
example, heavy menstrual bleedings, dysmenorrhea, pelvic 
pain) and systemic (depression, fatigue, headache, symptoms 
of irritable bowel syndrome, flares of bladder pain and/or of 
vestibulodynia, cyclic asthma attacks) symptoms, which are 
caused by local and systemic increase in the number of inflam-
matory molecules released by mast cells.
2. To maintain better physical and mental health women 
need stable levels of estrogen and progesterone. A stable level 
of estradiol is associated with a woman's better state of health 
as compared with the situation when its fluctuations occur.
3. During COCs selection for healthy women it is reasonable 
to give preference to COCs with short HFI (24+4, 26+2) com-
pared to the traditional regimen (21+7), since the reduction of 
HFI provides a more stable level of estradiol, reduces the risk 
of casual ovulation in case of missed pill and increases contra-
ceptive efficacy in comparison with the traditional regimen. In 
addition, it allows reducing the incidence of hormone-with-
drawal associated symptoms that affect the quality of life of 
women, couples and families.
4. Women, who have symptoms during COCs use with 21+7 
regimen (mastodynia, headache, bloating), which are associated 
with increase of endogenous hormone production should be rec-
ommended to switch to COC with shortened HFI (24+4, 26+2).
5. Selection of COC with a short HFI (24+4, 26+2) is especially 
important for women with PMS, heavy menstrual bleedings, pri-
mary dysmenorrhea, with a tendency to formation of functional 
ovarian cysts, bronchial asthma, menstrual migraine, arthritis, 
chronic pelvic pain associated with vulvodina, painful bladder 
syndrome/interstitial cystitis and irritable bowel syndrome.
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Т.Ф. Татарчук, д. мед. н., професор, член-кореспондент НАМН України, заступник директора з наукової роботи, завідувачка відділенням ендокринної гінекології ДУ «Інститут педіатрії, акушерства та гінекології ім. акад. 
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та інші автори
12 березня 2019 р. у Києві відбулося засідання Експертної ради з питань впливу маткових кровотеч на якість життя жінки, до роботи якої були залучені провідні вітчизняні та європейські фахівці.
Згідно з думкою міжнародних експертів (клінічні рекомендації Національного інституту здоров'я і якості медичної допомоги Великобританії та Міжнародної федерації гінекології та акушерства від 2018 р.), вибір тактики ведення 
пацієнтки визначається не результатом вимірювання крововтрати, а самопочуттям жінки (дистрес, зниження працездатності, сексуальної активності та якості життя).
Менструальні симптоми зазвичай є легкими і незначними або взагалі відсутні за умови, якщо менструальне запалення відповідає наступним трьом критеріям: «завершується» (відновлюється нормальна цитоархітектура 
тканини, перш за все ендометрія); обмежене в часі; адекватне і достатнє за інтенсивністю для завершення відновлення гістологічних та функціональних характеристик залучених тканин. Однак якщо локальне і системне 
запалення, асоційоване з менструацією, є надмірним за інтенсивністю і тривалістю, воно викликає різні патологічні симптоми. Тяжкі менструальні симптоми клінічно корелюють з місцевим та системним запаленням, яке не 
завершується (менструація є надмірною за тривалістю та інтенсивністю). Тому пригнічення менструального запалення є важливим для зменшення частоти проявів та інтенсивності менструальних симптомів і покращення якості 
життя жінок репродуктивного віку.
Для оптимізації фізичного та психічного здоров`я жінкам необхідні належні стабільні рівнів естрогенів та прогестерону. При виборі комбінованих оральних контрацептивів для здорових жінок доцільно віддавати перевагу 
препаратам із коротким безгормональним інтервалом (24+4, 26+2) у порівнянні з традиційним режимом (21+7). Скорочення цього інтервалу забезпечує більш стабільний рівень естрадіолу, знижує ризик випадкової овуляції в 
разі пропуску таблеток, підвищує резерв контрацептивної надійності в порівнянні з традиційним режимом, а також дозволяє зменшити частоту появи симптомів, асоційованих з відміною гормонів.
Ключові слова: резолюція Експертної ради, аномальні маткові кровотечі, менструальні симптоми, комбіновані оральні контрацептиви, безгормональний інтервал.
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Т.Ф. Татарчук, д. мед. н., профессор, член-корреспондент НАМН Украины, заместитель директора по научной работе, заведующая отделением эндокринной гинекологии ГУ «Институт педиатрии, акушерства и гинекологии 
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и другие авторы
12 марта 2019 г. в Киеве состоялось заседание Экспертного совета по вопросам влияния маточных кровотечений на качество жизни женщины, к работе которого были привлечены ведущие отечественные и европейские специалисты.
Согласно мнению международных экспертов (клинические рекомендации Национального института здоровья и качества медицинской помощи Великобритании и Международной федерации гинекологии и акушерства от 2018 г.),
выбор тактики ведения пациентки определяется не результатом измерения кровопотери, а самочувствием женщины (дистресс, снижение работоспособности, сексуальной активности и качества жизни).
Менструальные симптомы, как правило, являются легкими и незначительными или вообще отсутствуют при условии, если менструальное воспаление соответствует следующим трем критериям: «завершается» 
(восстанавливается нормальная цитоархитектура ткани, прежде всего эндометрия); ограничено во времени; адекватно и достаточно по интенсивности для завершения восстановления гистологических и функциональных 
характеристик привлеченных тканей. Однако если локальное и системное воспаление, ассоциированное с менструацией, является чрезмерным по интенсивности и продолжительности, оно вызывает различные патологические 
симптомы. Тяжелые менструальные симптомы клинически коррелируют с местным и системным воспалением, которое не заканчивается (менструация избыточна по продолжительности и интенсивности). Поэтому подавление 
менструального воспаления является важным для уменьшения частоты проявлений и интенсивности менструальных симптомов и улучшения качества жизни женщин репродуктивного возраста.
Для оптимизации физического и психического здоровья женщинам необходимы надлежащие стабильные уровни эстрогенов и прогестерона. При выборе комбинированных оральных контрацептивов для здоровых женщин 
целесообразно отдавать предпочтение препаратам с коротким безгормональным интервалом (24+4, 26+2) по сравнению с традиционным режимом (21+7). Сокращение этого интервала обеспечивает более стабильный 
уровень эстрадиола, снижает риск случайной овуляции при пропуске таблеток, повышает резерв контрацептивной надежности по сравнению с традиционным режимом, а также позволяет уменьшить частоту появления 
симптомов, ассоциированных с отменой гормонов.
Ключевые слова: резолюция Экспертного совета, аномальные маточные кровотечения, менструальные симптомы, комбинированные оральные контрацептивы, безгормональный интервал.
UTERINE BLEEDINGS AND QUALITY OF WOMAN'S LIFE
Resolution of Advisory Board
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Y.P. Vdovychenko, MD, professor, corresponding member of the NAMS of Ukraine, first vice rector of P.L. Shupik NMAPE, president of the Ukrainian Association of Perinatal Medicine
A. Graziottin, MD, professor, director of Center for Gynecology and Medical Sexology of H. San Raffaele Hospital in Milan, Italy
V.V. Kaminskyi, MD, professor, corresponding member of the NAMS of Ukraine, head of the Obstetrics, Gynecology and Reproductology Department of P.L. Shupyk NMAPE, chief specialist in Obstetrics and Gynecology at the Ministry of Health 
of Ukraine, executive director of the Association of Obstetricians and Gynecologists of Ukraine
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and other authors
On March 12, 2019, an Advisory Board on impact of uterine bleedings on the quality of life of a woman was held in Kyiv, with participation of leading Ukrainian and European experts.
According to opinion of international experts (guidelines of the UK National Institute for Health and Care Excellence and the International Federation of Gynecology and Obstetrics from 2018), the choice of patient management tactics is not 
determined by measuring blood loss, but by the patient’s well-being (distress, decrease of work ability, sexual activity and quality of life).
Menstrual inflammation is phisiological and menstrual symptoms are usually mild/minor or absent when three criteria are fulfilled: resolving (normal cytoarchitecture of the tissue is reconstructed, endometrium first); limited in time; adequate 
and sufficient by intensity to finalize the reconstruction to the histological and functional characteristics of the different tissues involved. At the same time, if local and systemic inflammation associated with menstruation is excessive by 
intensity and duration, it can cause different pathological symptoms. Severe menstrual symptoms are clinically correlated with local and systemic inflammation, which is not resolving (menstruation is excessive in duration and intensity). 
Therefore, reducing menstrual inflammation is important to reduce the frequency and intensity of menstrual symptoms and improve the quality of life of women of reproductive age.
Women need appropriate stable levels of estrogen and progesterone to optimize their physical and mental health. During combined oral contraceptives selection for healthy women it is reasonable to give preference to contraceptives with short 
hormonal free interval (24+4, 26+2) compared to the traditional regimen (21+7), since the reduction of this interval provides a more stable level of estradiol, reduces the risk of casual ovulation in case of missed pill, increases contraceptive 
efficacy in comparison with the traditional regimen and reduce the incidence of hormone-withdrawal associated symptoms.
Keywords: resolution of Advisory Board, abnormal uterine bleeding, menstrual symptoms, combined oral contraceptives, hormonal free interval.
